Rapid Fire
Qdenga Vaccine for Dengue
- 03 Apr 2026
- 2 min read
India has approved Takeda's TAK-003 (Qdenga), its first dengue vaccine, cleared by the Subject Expert Committee (SEC) under the Drugs Controller General of India (DCGI) for individuals aged 4 to 60 years marking a historic shift from reactive vector control to preventive public health strategy.
- Qdenga: It is a tetravalent dengue vaccine tested on 28,000+ participants and approved in 40+ countries.
- TAK-003 is a disease-modifying vaccine, not a transmission-blocking one. It reduces clinical severity but does not prevent infection or eliminate outbreaks.
- Unlike earlier vaccines, it does not require prior dengue infection testing, making rollout easier.
- SEC has mandated post-marketing studies across regions and serotype patterns to assess real-world effectiveness in India.
- Key Limitations: Dengue is caused by four serotypes (DENV-1 to DENV-4). While TAK-003 is highly effective against DENV-2 (its genetic backbone), its efficacy is notably lower against DENV-3 and DENV-4, especially in "seronegative" individuals (those never previously infected).
- India's dengue epidemiology is shifting while DENV-3 is rising (contributing 20–30% of cases) in several regions, potentially reducing the vaccine's population-level impact.
- Cost concern: The full two-dose course is estimated to cost between Rs 6,000 and Rs 12,000, posing significant affordability and compliance challenges for rural and low-income populations.
- Indigenous Pipeline: India is developing ‘DengiAll’ (developed by Panacea Biotec and ICMR) which aims for more balanced protection across all four serotypes, potentially available by 2027.
| Read more: DengiAll |
